In a second trial, 11 patients with refractory/relapsed B-cell lymphoma were treated with CD19-specific CAR-T cells and the PD-1-blocking antibody nivolumab [57]. Here, PDCD1 is linked to B-cell non-Hodgkin lymphoma.